Drug Profile
GSK 257049
Alternative Names: 257049; Circumsporozoite protein hepatitis-B surface antigen fusion protein- GSK; CSP-HBsAg - GSK; CSP-HBsAg/SBAS2-GSK; FSV-1-malaria-vaccine-GSK; GSK-257146; GSK-RTS,S/AS01; GSK257049; Malaria vaccine 257049 - GSK; Mosquirix; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - GSK; Plasmodium falciparum CSP/HBsAg - GSK; Plasmodium falciparum CSP/HBsAg subunit vaccine - GSK; Plasmodium falciparum malaria vaccine 257049; Profilam; QS 21 stimulon adjuvanted malaria vaccine - Agenus/GSK; RTS,S; RTS,S/AS; RTS,S/AS01; RTS,S/AS01B; RTS,S/AS01E; RTS,S/AS02; RTS,S/AS02A; RTS,S/AS02D; SB-257049Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; Malaria Vaccine Initiative; PATH; University of Oxford
- Class Antimalarials; Parasitic vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Falciparum malaria
Most Recent Events
- 11 Nov 2022 GlaxoSmithKline completes a phase II trial in Falciparum malaria (In infants, Prevention) in Ghana and Kenya (IM) (NCT03276962)
- 06 Sep 2022 WHO grants prequalification to GSK 257049 for Falciparum malaria
- 17 Aug 2022 GlaxoSmithKline and PATH completes a phase II trial in Falciparum malaria (In adults, Prevention) in Kenya (IM) (NCT04661579)